Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab plus surgery for moderate to severe hidradenitis suppurativa
NL-OMON47251Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Humira + surgery with Placebo + surgery (2 arms). Primary endpoint: HiSCR at Week 12. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON47251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47251.